Autres langues OptiNose, Inc.

Actions

OPTN

US68404V1008

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
1,08 ^USD	+0,93 %		-2,70 %	-16,28 %

14/05	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	OptiNose, Inc. annonce ses résultats pour le premier trimestre terminé le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	09/05
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	25/04
Transcript : OptiNose, Inc. - Special Call	25/04
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	25/04
OPTINOSE, INC. : Lake Street reste à l'achat	18/03
Sector Update: Health Care Stocks Steady Premarket Monday	18/03
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	15/03
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	14/03
OPTINOSE, INC. : HC Wainwright persiste à l'achat	11/03
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	07/03
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	07/03
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	18/01
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis	06/12
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	06/12
Transcript : OptiNose, Inc., Q3 2023 Earnings Call, Nov 09, 2023	09/11
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues OptiNose, Inc.

Actions

OPTN

US68404V1008

Autres langues

Filtres